Sharemaestro Newsreel

H.C. Wainwright reiterates Buy on Akebia stock, $6 target

Form 8K Viatris Inc For: 6 August By Investing.com

This article announces that Viatris Inc. has filed a Form 8K on August 6th. The filing is presented without additional details or commentary, focusing solely on the event itself. The article also includes stock performance for VTRS and links to other related market data.

Cronos Group (NASDAQ:CRON) Shares Gap Up After Better-Than-Expected Earnings

Lantheus Holdings Inc earnings beat by $0.26, revenue topped estimates

Lantheus Holdings Inc (LNTH) reported strong second-quarter results, beating analyst expectations for both EPS and revenue. The company announced an EPS of $1.55 against an estimate of $1.29, and revenue of $388.2 million, surpassing the consensus of $362.32 million. LNTH's stock has shown significant …

FMR LLC discloses 8.3% Viatris Inc (VTRS) ownership, over 96M shares

FMR LLC has disclosed an 8.3% beneficial ownership in Viatris Inc. (VTRS), amounting to 96,362,102.65 shares. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same shares and stake percentage. This information comes from a SCHEDULE 13G …

UBS Adjusts Price Target on Elanco Animal Health to $33 From $31, Maintains Buy Rating

UBS has increased its price target for Elanco Animal Health to $33 from $31, while reiterating a Buy rating on the stock. This adjustment follows Elanco's Q2 2026 earnings call, where the company reported rising adjusted earnings and revenue and lifted its 2026 outlook. …

Amylyx Pharmaceuticals Q2 Earnings Call Highlights

Amylyx Pharmaceuticals expects top-line data from its pivotal Phase III LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH) by early September. The company is preparing for a potential U.S. launch in 2027, contingent on positive data and regulatory approval, and is also advancing other …

Cronos Group Inc.

Cronos Group Inc. announced strong second-quarter business results for 2026, with net revenue increasing by 51% year-over-year on an organic, constant-currency basis. Following this announcement, the company's shares (T.CRON) saw an increase of $0.44, reaching $4.24. This performance indicates significant growth for the cannabis …

H.C. Wainwright reiterates Buy on Akebia stock, $6 target By Investing.com

RedHill Biopharma Reschedules Quorum-Delayed AGM to August 7

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Xeris Pharmaceuticals earnings missed by $0.19, revenue topped estimates

Bausch Health CEO joins Bausch + Lomb board of directors By Investing.com

Bausch Health CEO Thomas J. Appio has been appointed to the board of directors of its subsidiary Bausch + Lomb Corporation. This move, along with the appointment of three other new directors and the resignation of four existing ones, aligns with Bausch Health's significant …

Amylyx Pharmaceuticals 2Q Loss/Shr 39c >AMLX

Amylyx Pharmaceuticals reported a second-quarter loss per share of 39 cents. This financial update is significant for investors following the company's performance. The results provide insight into the company's recent financial health.

Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss

Xeris Biopharma reported a Q2 2026 revenue beat of $92.1 million, surpassing Wall Street estimates, but missed EPS expectations with a loss of $0.18 per share. The company attributed the EPS miss primarily to a one-time non-cash GAAP charge related to convertible note remeasurement. …

Cronos Group Reports Record Q2 2026 Revenue of $53 Million

Cronos Group Inc. reported record net revenue of US$53 million for Q2 2026, a 58% year-over-year increase, alongside a significant jump in gross profit and a return to net income. The company saw strong growth across cannabis flower and extract sales in Canada, Israel, …

Cronos stock jumps after Q2 beat (CRON:NASDAQ)

Cronos Group (CRON) saw its stock jump over 10% in premarket trading following better-than-expected Q2 2026 financial results. This surge occurred despite the Canadian firm revealing it is under an anti-dumping investigation in Israel. The company reported $19.6 million in net revenue for the …

Prestige Consumer Healthcare Inc. 2027 Q1 - Results - Earnings Call Presentation (NYSE:PBH) 2026-08-06

Prestige Consumer Healthcare Inc. (PBH) has released its Q1 2027 earnings call presentation. The company reported an EPS of $0.98, beating estimates by $0.10, and revenue of $265.71M, surpassing expectations by $15.39M, representing a 6.48% year-over-year increase. This article provides access to the slide …

Sonoma FY2027 Q1 earnings: 60% revenue growth moves EBITDA positive

Here's What Key Metrics Tell Us About Zoetis (ZTS) Q2 Earnings

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

RedHill Biopharma (NASDAQ: RDHL) adjourns AGM after quorum shortfall

RedHill Biopharma Ltd. announced the adjournment of its Annual General Meeting of Shareholders, originally scheduled for August 6, 2026, due to a lack of a legal quorum. The meeting has been rescheduled to reconvene on August 7, 2026, at 3:00 p.m. Israel time at …

Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. increased its stake in Pacira BioSciences, Inc. by 24.5% in the first quarter, now owning 235,427 shares. The company reported strong Q2 revenue and EPS, exceeding analyst expectations, but its 2026 revenue guidance fell below consensus. Analyst sentiment is mixed, with …

BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary

BioAge Labs, Inc. reported its second-quarter 2026 results, showing flat revenue year-over-year at $2.45 million and a wider net loss, with a diluted loss per share of $(0.58). Despite the financial performance, the company highlighted positive clinical progress for BGE-102, advancement in its QUELL-CV …

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

Xeris Biopharma (XERS) reported Q2 2026 revenue of $92.1 million, a 28.7% year-over-year increase, surpassing the Zacks Consensus Estimate. However, the EPS of $0 missed the consensus estimate of $0.02. Key product revenues varied, with Recorlev showing significant growth while Gvoke and Keveyis experienced …

(XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M - $390M, vs. FactSet Est of $385.9M

Xeris Biopharma Holdings, Inc. announced its full-year 2026 revenue guidance, projecting a range of $385 million to $390 million. This forecast is in line with FactSet's estimated revenue of $385.9 million. The company also provided an update on its second-quarter earnings for 2026.

BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside

BioCryst Pharmaceuticals, Inc.'s average 12-month price target has been lowered slightly from $21 to $20.82 by 11 analysts, with forecasts ranging from $12 to $32 per share. This new target suggests a potential upside of approximately 131% based on the Aug. 4 closing price. …

Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Dimensional Fund Advisors LP significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 119% in the first quarter, now holding 2.69 million shares valued at $25.6 million. This move is consistent with a generally positive outlook from analysts, who have assigned a "Moderate Buy" …

Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds

Zoetis Inc. (NYSE: ZTS) reported Q2 adjusted earnings of $1.87 per share, beating consensus, but sales of $2.468 billion missed estimates, showing flat year-over-year revenue. The company noted softer demand in the companion animal market due to lower clinic visits and pet owner price …

Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ:LNTH) reported strong Q2 CY2026 results, exceeding Wall Street expectations with revenue of $388.2 million and non-GAAP EPS of $1.55. Despite impressive five-year revenue and EPS growth, recent performance shows a slowdown, with analysts projecting a revenue decline for the next 12 …

Anika Therapeutics (ANIK) Insider Gary Fischetti Buys 2,000 Shares, Increasing Stake to 54,015 Shares

Gary Fischetti, a Director at Anika Therapeutics Inc (ANIK), recently purchased 2,000 shares at $20.53 each, increasing his total holdings to 54,015 shares. This transaction, valued at approximately $41,060, follows a trend of insider buying at the company, with 3 insider buys and no …

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Sonoma Pharmaceuticals (NASDAQ: SNOA) reported record quarterly revenue of $6.4 million in the first quarter, marking a significant increase from the prior-year period. The company also achieved positive EBITDA for the first time, reaching $0.1 million, and improved its gross profit margin to 40%. …

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

Thomas J. Appio, CEO of Bausch Health Companies Inc., has been appointed to the board of directors of Bausch + Lomb Corporation, a subsidiary of Bausch Health. This appointment was effective August 5, 2026. The announcement was made by Bausch Health Companies Inc.

Janus Henderson Group PLC Grows Stake in ANI Pharmaceuticals, Inc. $ANIP

Janus Henderson Group PLC significantly increased its stake in ANI Pharmaceuticals, Inc. during the first quarter of 2026, boosting its holdings by 1,308.1% to 109,552 shares valued at approximately $8.4 million. This move comes as ANI Pharmaceuticals reported strong quarterly earnings, beating analyst estimates …

BioAge Labs, Inc. (BIOA) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of BioAge Labs, Inc. (BIOA) stock, including its current price, historical data, company profile, and financial performance. It highlights key financial metrics, analyst ratings, and recent stock performance compared to the S&P 500, detailing the company's …